Dr. Sogol Mostoufi-Moab Featured in HemOnc Today as Expert on Surveillance Guidelines for Endocrine Late Effects

Published on

Sogol Mostoufi-Moab, MD, MSCE, a dual-certified pediatric oncologist and endocrinologist with CHOP’s Endocrine Late Effects after Cancer Therapy (ELECT) Program, was featured as an expert in a recent HemOnc Today article about guideline recommendations to surveil pediatric cancer survivors and manage endocrine-related late effects of therapy. One set of existing guidelines was issue by the Children’s Oncology Group, and Dr. Mostoufi-Moab called these “an exhaustive and comprehensive effort,” adding, “As we have more and more adult survivors of childhood cancer, the importance of these guidelines will be more evident.” The article also covered topics including how the risk for endocrine complications is dependent on factors such as tumor location, and the need to harmonize U.S. and international guidelines. It also emphasized the dangers of failing to screen pediatric cancer survivors as they age into adulthood: “Educating our patients is a huge responsibility,” said Dr. Mostoufi-Moab.